PolyPid (NASDAQ:PYPD) Posts Earnings Results, Beats Expectations By $0.01 EPS

PolyPid (NASDAQ:PYPD – Get Rating) announced its earnings results on Wednesday. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.01, MarketWatch Earnings reports. During the same quarter in the previous year, the firm earned ($0.47) earnings per share.

Shares of PolyPid stock traded up $0.20 on Thursday, reaching $4.77. 74,284 shares of the stock were exchanged, compared to its average volume of 40,629. PolyPid has a 1-year low of $3.92 and a 1-year high of $9.64. The business has a fifty day moving average price of $5.21 and a two-hundred day moving average price of $5.69. The firm has a market capitalization of $81.31 million, a PE ratio of -2.10 and a beta of 0.83.

Several institutional investors have recently modified their holdings of PYPD. Morgan Stanley acquired a new position in shares of PolyPid during the second quarter worth about $32,000. Millennium Management LLC grew its position in PolyPid by 153.5% during the second quarter. Millennium Management LLC now owns 56,530 shares of the company’s stock worth $512,000 after buying an additional 34,227 shares during the period. Geode Capital Management LLC grew its position in PolyPid by 12.2% during the third quarter. Geode Capital Management LLC now owns 12,545 shares of the company’s stock worth $97,000 after buying an additional 1,364 shares during the period. UBS Group AG grew its position in PolyPid by 32.7% during the third quarter. UBS Group AG now owns 204,555 shares of the company’s stock worth $1,592,000 after buying an additional 50,395 shares during the period. Finally, Bank of America Corp DE acquired a new position in PolyPid during the fourth quarter worth about $52,000. Institutional investors and hedge funds own 20.84% of the company’s stock.

PYPD has been the subject of a number of research reports. Raymond James reduced their target price on shares of PolyPid from $23.00 to $17.00 and set a “strong-buy” rating for the company in a report on Friday, February 11th. Zacks Investment Research raised shares of PolyPid from a “sell” rating to a “hold” rating in a report on Wednesday, April 13th.

PolyPid Company Profile (Get Rating)

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs.

See Also